Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

This study has been completed.
HRA Pharma
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ) Identifier:
First received: February 10, 2006
Last updated: November 14, 2012
Last verified: November 2012
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.

Condition Intervention Phase
Drug: ulipristal acetate
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Shrinkage of Fibroids - Size of Fibroids [ Time Frame: 3 months (baseline to end of treatment) ]
    The primary outcome, fibroid volume, was calculated by an ellipsoid formula (π/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.

Secondary Outcome Measures:
  • Quality of Life [ Time Frame: 3 months (Baseline to end of treatment 1) ]
    The short form-36 (SF-36)and Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaires were given before and at treatment end with scales of 0 - 100. SF-36 scales = mental and physical well-being. The UFS subscales are symptom severity, concern, activities, energy and mood, control, self-consciousness, sexual functioning compiled into an overall QOL score. Higher results indicate better QOL on all but symptom severity (higher = worse). The change in scores from baseline to end of treatment was calculated.

Enrollment: 72
Study Start Date: February 2006
Study Completion Date: August 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ulipristal acetate -20 mg
20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
Drug: ulipristal acetate
ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
Other Name: VA2914; CDB-2914
Active Comparator: ulipristal acetate - 10 mg
10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
Drug: ulipristal acetate
10 mg given daily for three menstrual cycles or 90 - 102 days
Other Name: VA2914; CDB2914
Placebo Comparator: Placebo
Placebo taken daily for three menstrual cycles or up to 102 days in each study phase
Drug: placebo
placebo given once daily for 3 menstrual cycles or 90 - 102 days

  Show Detailed Description


Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Female gender-to evaluate effects in the target population for clinical trials.
  • History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin:
  • Excessive uterine bleeding will be evidenced by either of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss;


  • Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection.
  • Uterine leiomyoma(ta) of at least 2 cm size.
  • In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Interval use of over-the-counter drugs is acceptable but must be recorded.
  • Menstrual cycles of 24 - 35 days.
  • Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered to improve red blood cell counts.
  • Willing and able to comply with study requirements.
  • Age 25 to 50.
  • Using mechanical (condoms, diaphragms) sterilization or abstinence methods of contraception for the duration of the study.
  • Negative urine pregnancy test.
  • Body mass index (BMI) less than or equal to 33, if a surgical candidate or less than or equal to 35, if not a surgical candidate.
  • Creatinine less than 1.3 mg/dL.
  • Liver function tests within 130% of upper limit.
  • If interested in hysterectomy, no desire for fertility.


  • Significant abnormalities in the history, physical or laboratory examination.
  • Pregnancy.
  • Lactation.
  • Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year.
  • Unexplained vaginal bleeding.
  • History of malignancy within the past 5 years.
  • Use of estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry, including transdermal, injectable, vaginal and oral preparations.
  • Use of agents known to induce hepatic P450 enzymes; use of imidazoles.
  • Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that affect menstrual cyclicity.
  • Follicle stimulating hormone (FSH) greater than 20 IU/mL.
  • Untreated cervical dysplasia.
  • Need for interval use of narcotics.
  • Abnormal adnexal/ovarian mass.
  • Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months.
  • Contradiction to anesthesia, for women planning surgery.
  • Genetic causes of leiomyomata.
  • Previous participation in the study.
  • Known recent rapid growth of fibroids, defined as a doubling in size in six months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00290251

United States, Maryland
NIH Clinical Center
Bethesda, Maryland, United States, 20891
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HRA Pharma
Principal Investigator: Lynnette K Nieman, MD NICHD, NIH
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Identifier: NCT00290251     History of Changes
Other Study ID Numbers: 060090
1ZIAHD000637-17 ( US NIH Grant/Contract Award Number )
Study First Received: February 10, 2006
Results First Received: October 28, 2011
Last Updated: November 14, 2012

Keywords provided by National Institutes of Health Clinical Center (CC):
Uterine Fibroids

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 24, 2017